Tag Archives: growing

Treating Cannabis Like A Fine Wine

By Sean Creamer
No Comments

The experience in both wine and cannabis starts with ritual: swirling, inhaling, letting heat or air coax the plant’s chemistry to life. Where wine has long relied on sommeliers to guide that moment, cannabis has spent decades without an equivalent voice to explain how cultivation, curing, and preparation shape what a consumer feels.

The emergence of the Ganjier is an attempt to fill that gap. Created by a group of cultivators, hashmakers, historians, and retailers, including figures like Kevin Jodrey, Swami Chaitanya, Nick Tanem, and Derek Gilman, the Ganjier Council is designed to professionalize cannabis evaluation and service. Think of it as the cannabis world’s version of the Court of Master Sommeliers: a certification built around sensory training, product knowledge, and the language needed to communicate quality.

Reverence for process is exactly what the Ganjier certification program aims to formalize. Kevin Jodrey, the renowned cultivator and original architect of the curriculum, describes Ganjiers as interpreters. “Ganjiers fit into the conversation as translators, somebody who clarifies language, so that when you say something to me, and I say something to someone else, it means the same thing.” It mirrors the work of sommeliers, a comparison Jodrey makes explicitly: “That’s really what sommeliers do, they translate wine into language that allows people to understand what to expect.”

As legalization accelerates and price compression pushes products toward uniformity, this shared language, the ability to turn sensory experience into common understanding, may be cannabis’s most powerful differentiator.

 

Meet the Experts Teaching the World to Taste Cannabis like Fine Wine

The modern Ganjier began as something far more personal. Jodrey recalls its earliest moment taking shape at home. “The Ganjier was invented in my kitchen. My son came up with the name, he said, ‘Dad, you’re a Ganjier, you’re a cannabis culturalist. You’re all things cannabis.’” What started as a family nickname soon resonated more widely. As legalization gained momentum, Green Flower founders Max Simon and Derek Gilman approached Jodrey with a proposal. “They came to me and said, Hey, Kev, we have an idea that we would like to create a program that highlights the nuances of cannabis in a way that allows the complex world to be brought to light so that customers, new people, consumers can see the picture in a way they haven’t.”

Shaping that clarity took work. Over several years, Jodrey and a team of eighteen practitioners debated how to define cannabis quality in a way that could stand the test of time. “It allowed the 18 of us, over the course of  7,000 hours in a multi-year period, to brawl it out and determine how to look at something in an objective manner. It was an idea of how to create cannabis connoisseurship that has a hundred-year life.”

Tanem, a California-based hashmaker and founding Ganjier Council member, remembers how the Council ultimately formed around that mission. “Derrick Gilman collected a number of us professionals that had skill sets in different areas throughout the industry, from breeding to cultivation to the law to history to extraction, you name it. The goal was to cover all bases via a program that would teach what quality is in cannabis. “People don’t really know how to assess quality, and so that’s a big part of what the Ganjier does,” said Tanem. “We really give a full background of the industry, from cultivation to law to the history to extraction to customer interaction protocols, etc.”

The path cannabis is now traveling mirrors the evolution of other connoisseur markets. Jocelyn Sheltraw, founder of The Budist, a cannabis scoring and education platform, notes that wine, beer, and coffee all matured through codification. “It’s just understanding how other connoisseur markets have evolved, and really studying the history of how consumers come to appreciate products. Whether you look at wine, beer, or coffee, they all use the same 100-point system created by Robert Parker in the late 1970s and early 1980s.” 

She emphasizes that no scoring system gains traction without guidance for interpreting it. “It took the Sherpas, it took the educators to translate that to consumers across all of those industries.” Competitions and community forums also played a role. “Competitions were a major part of drawing light on quality, and the oldest wine competition in the United States actually dates back to the 1850s.” 

Cannabis is now following the same arc, with its own judging culture, from legacy region cups to large-scale events like the upcoming MJBiz Con awards on December 2nd-5th, which bring brands, cultivators, and reviewers under one roof to evaluate products on shared terms. Cannabis connoisseurship is now entering that same phase: a shift from tradition held in pockets to a shared, teachable system of evaluation. The Ganjier is its first attempt at building a unified language.

Training and the Craft of Evaluation

If the origins of the Ganjier reflect cannabis culture’s past, the curriculum represents its future. The program is designed to function much like formal wine education, combining sensory discipline, technical learning, and service training. Students work through extensive online modules and then take part in in-person instruction led by multiple council members with different palates and professional backgrounds. 

Tanem describes the value of that diversity. “Students who come through the Ganjier program not only do two days of in-person training, but they also do anywhere from two weeks to two years of online training where they go through all of the different aspects of the industry.” Once students come out for the in-person class, there are four or five instructors or council members who provide different opinions and education. “For instance, from Swami [Chaitanya], who wants a smoother smoke and a well-cured product he calls vintage, to people like myself who have the ears to the streets,” said Tanem. “We have a lot of council members that are in retail today, in cultivation, in extraction. Having that variation in how we present what quality is, because quality can be subjective.”

A major part of that training is undoing the industry’s fixation on THC percentage. “We teach away from promoting high THC products,” Tanem says. “People want the highest THC, and we really want to educate people against that. We talk about the other volatile compounds, from sulfurs to esters to terpenes. There is a lot more to cannabis than just high THC numbers.”

The structure for this deeper analysis comes through the Systematic Assessment Protocol, or SAP, the sensory backbone of the curriculum. Jodrey explains it as a guided way to evaluate cannabis in stages. “The SAP is basically a digital scorecard with criteria that, when you touch the category, allows you to understand what this category is and how we look at it.” First up, according to Jodrey, is aroma, followed by appearance, then combustion or flavor, and then experience. The approach distinguishes between objective traits and subjective preferences. “Very volatile cannabis indicates good storage and good production,” he notes. “But a variety with low aroma might be perfect for someone who lives with their family, and the smell of pot offends them.”

Even outside the formal Ganjier curriculum, people who cultivate, process, and evaluate cannabis are running into the same limitation: combustion obscures the very subtleties the SAP is designed to measure. Former cultivator and current PAX Labs VP of Marketing Justin Tacy says this was a constant frustration long before he ever entered the device world. 

“As a cultivator, it was always frustrating to have people take what I spent years and years developing and just throw it in a bong and rip the whole gram in one go,” said Tacy. “That gives you the psychoactive effects, but it doesn’t really give you appreciation for the nuances around different terpenes and flavors.” 

Glassware and devices in cannabis are a crucial vehicle for connoisseurship. The same way wine glass design affects aroma delivery and perception, the tools used to consume cannabis can either sharpen or blunt the sensory experience. 

“It [dry air vaporization] really allows you to taste the genetics the way the cultivator intended, and pick up some of those more nuanced effects that only come from vaporizing certain terpenes versus combusting them,” Tacy noted. 

The point underscores a larger shift within cannabis connoisseurship, which is how you smoke matters. Just as glassware shapes how wine expresses its structure, the way flower is heated determines which compounds rise to the surface and which are muted or lost. That emphasis on controlled, repeatable sensory experience is exactly what the Ganjier SAP aims to formalize. 

“Wine is picking up complexity and notes and creating identification so people can understand,” Jodrey says. “We provide that, but we also provide other factors that wine does not have, which are the sustainability of aroma and penetration of aroma.” 

Behind the scenes, the Council built the curriculum piece by piece. “We broke this thing into pieces: cannabis science, law, history, retail, cultivation.” The team then went and found the people who fit into all those pieces, enabling the creation of the curriculum. “The Ganjier is a book; we all wrote a couple of chapters each in this book,” said Jodrey. “We created a common respect that was collaborative, and it was a golden time to create a language that we knew would hold up.”

That language now feeds into the broader connoisseurship ecosystem. Sheltraw describes the relationship between the Ganjier program and consumer platforms like The Budist. “Ganjier is the educational platform, equivalent of the sommelier program. Budist is the commercial platform where you apply that knowledge. Budist would then be the Wine Advocate, or Budist would be Vivino.” She emphasizes the importance of consistent judging methods. 

The SAP supplies the structure behind those evaluations. “With the SAP, there are 50 different data points. You are looking at trichome density, bud texture, and the complexity of flavors and aromas. Just to assess one flower can easily take over an hour.” And at the consumer level, the system becomes more approachable. “At Budist, we still use that same 100 point system, like all of these other major industries, but simplified for consumers. There are really four key attributes: aroma, appearance, flavor, and effect.”

Together, these elements turn the Ganjier curriculum into something much larger than a training course. It is a shared methodology, one that moves cannabis evaluation away from potency myths and toward a transparent, structured language of quality.

How Ganjiers Will Reshape Retail, Cultivation, and Brand Strategy

The rise of the Ganjier is beginning to reshape how cannabis is bought, taught, and experienced. What started as a sensory certification is now influencing every corner of the industry, from retail counters to events to tourism. 

“We are now having Bud Bars at weddings and events instead of alcohol bars, where Ganjier would be the budtender at a Bud Bar at a wedding,” Tanem said. “We are also seeing Ganjier in so many different spaces and aspects of the industry from buyers for dispensaries to QC to the head of distro, the head of sales departments, lead cultivation techs, and femmers [A femmer is someone who carries out the processes used to create feminized cannabis seeds, typically through controlled stress techniques, colloidal silver sprays, or silver thiosulfate (STS) applications that suppress male flower development.].  Tanem notes that recreational smokers and industry participants want to become Ganjiers for a whole host of reasons. 

As such, the credential has begun to create its own global community. “Every single time I go out in the field, whether I am in Hawaii or Barcelona or Berlin or Thailand, I will pull up at an event, and there are other Ganjiers there, and it is a congregation. They know each other; they can build from that,” Tanem says. These gatherings reinforce a shared standard, which then filters back into consumer education.

But even as connoisseurship gains ground, most consumers still operate via narrow decision-making looks built around potency, price, and whatever happens to be familiar. Without time or instruction at the point of sale, people default to what they know, a pattern that obscures the meaningful aspects of quality. Tacy, who spent a decade cultivating flower before joining PAX, sees this as one of the industry’s largest hurdles. 

“The market rushed to easy-to-understand numbers, high THC, weight, and maybe the color of the product, ” said Tacy. “Those are driving a lot of the industry versus what’s the value and experience you’re getting for that dollar.”

The point echoes what Ganjiers confront daily: as long as potency remains a stand-in for quality, the nuances cultivators labor to express remain out of reach for consumers. 

Jodrey frames the market context driving this need for guidance. Disposable income controls the purchase. Ninety to ninety-five percent of all purchases in cannabis are fundamentally price-driven,” he said. Education becomes the tool that helps consumers choose based on fit rather than strength or discount. Retail environments are already adjusting. “What you have to do is create a situation that lets people feel relaxed, and Ganjiers help you understand what is available in the world of cannabis so you can make better choices. That changes entire businesses,” said Jodrey. 

This vision aligns with the broader consumer landscape that Sheltraw sees emerging. “It will be very similar to what we see in wine. You are going to see your Ganjier working at cannabis retail, and as tourism evolves, you will see Ganjiers at farms educating consumers.” That presence will be omnichannel. “Wherever the consumer is, whether it is digital, social, dispensaries, or farms, we are going to see Ganjiers assisting customers.” Consumer knowledge is limited, and people are doing what they’ve done in the past; consumers are purchasing based on price point and THC level. Professional evaluation helps bridge that gap, and brands are beginning to realize that connoisseurship can also be a strategy. “Brands in cannabis recognize that this can be the impact of what we are doing to get out of this price and potency trap,” says Sheltraw. 

In a market where sameness is easy and differentiation is hard, the Ganjier offers something rare: a way to raise the value of cannabis through understanding, story, and experience.

Cheers!

The same rituals that open a glass of wine or a jar of cured flower remind us that tasting is as much interpretation as it is sensation. 

As cannabis moves from prohibition to professionalism, the Ganjier represents the shift from novelty to craft, from a scattered vocabulary to a shared one. Nick Tanem sees that future taking shape as new markets mature and consumers search for guidance on quality. Kevin Jodrey frames it even more directly. 

“The Ganjier is just really meant to create a language, fundamentally a language, that everyone speaks from store to store. So that when you say a strain does this, it translates to that somewhere else. It is language. It is understanding.” In that understanding lies the foundation of cannabis connoisseurship espoused by the Ganjier Council.

Get your Ganjier certificate here.

Hear more from Kevin Jodrey on the Inovating Cannabis Podcast.

Hear more from Nick Tanem on the Innovating Cannabis Podcast.

 

The State Of New York’s Cannabis Industry 2025

By Pam Chmiel
No Comments

Jason Ambrosino, a disabled Army veteran and founder of Veterans Holdings, entered the New York market in 2019 under the state’s hemp program with the goal of cultivating and manufacturing cannabis. But despite holding a 5,000-square-foot indoor cultivation license, he decided not to build out his facility. The reason, he says, is simple: “The registered organizations (ROs) in New York State own the flower industry. They own it. You’re not going to break in.”

Ambrosino explained that the state’s vertically integrated ROs, many of which started as medical operators, dominate the adult-use flower market with massive 100,000-square-foot indoor canopies and the ability to negotiate favorable energy rates. “The number one driver of indoor flower price anywhere is electricity cost,” he said. “Where I am in New York State, it’s 23 cents a kilowatt hour. The ROs can negotiate directly for 7, 8, or 9 cents per kilowatt-hour because of their size. There will never be a day when I can operate in the market alongside them, because it costs me twice as much to grow as it does them.” He said that disparity makes small-scale cultivation unviable for most new entrants.

Ambrosino estimates that it could cost him roughly $600 per pound to grow cannabis, while the ROs can do it for about half that. “You don’t really think about it until you end up paying for a license, only to find out the utility prices are so high that you can’t make it work,” he said.

He believes the state’s adult-use rollout created an illusion of opportunity for small hemp farmers and microbusinesses. “They used the illusion of inclusion to gain public support,” he said. “They built protections that were meant to keep ROs out for three years to create a level playing field, but these protections were stripped away after enough lobbying dollars were spent.”

According to Ambrosino, large operators pressured lawmakers by withholding financial commitments to social equity programs until they received favorable terms. “They held them hostage,” he said. “They told lawmakers, ‘We’re not going to pay you any of that money until you give us a more favorable law.’ So, they changed it.”

The result, he says, is a market where ROs hold most of the canopy, while smaller cultivators face high costs, limited access, and few realistic paths to profitability. “Right now, microbusinesses are structured for failure,” Ambrosino said. “They’re trying to sell flower at $60 when dispensaries can get indoor-grown product from ROs for $30 or $35. You can’t compete with that.”

Mismatched Policy, Manipulated Data, and a Market Set to Run Dry

Ambrosino says the Office of Cannabis Management (OCM) has failed to recognize the growing imbalance between large registered organizations and small cultivators. “The data OCM puts out is very manipulated and questionable,” he said. “They conflict with what they report from one day to the next. One day, there’s not enough canopy, the next day, there’s too much. It’s all over the place. They’ll show you all the potential canopy of adult-use license holders, but the reality is 80% of them aren’t growing, or they’re only using part of their allotted space. Meanwhile, the ROs are operating at a massive scale.”

He believes this disconnect has led policymakers to think there’s an oversupply problem when in reality there’s a shortage of affordable biomass. “OCM looks at flower canopy, not biomass canopy,” Ambrosino said. “We don’t have enough biomass to produce distillate, and distillate is what sets the price for everything.”

Ambrosino, who sits on the board of the Association of New York Cannabis Processors, says the solution starts with expanding outdoor cultivation. “We’ve been lobbying the state to raise the outdoor cap from one acre to five,” he explained. “They keep saying there’s enough canopy, but that’s not true if you want a functioning processing and manufacturing sector.”

He also believes OCM steered small farmers in the wrong direction. “They convinced these guys to grow indoors when they had no capital to begin with,” he said. “Outdoor grows are cheaper, more sustainable, and can produce terpene-rich material that’s perfect for extraction. Giving up those outdoor licenses was the worst thing they could have done.”

Ambrosino sees the industry’s structural problems fueling a deeper issue: product inversion. “Inversion is like a cancer tumor,” he said. “Everyone — dispensaries, processors, cultivators — is supporting it. If OCM just cuts it out overnight, the market will bleed to death. We have to shrink the tumor first. The only way to do that is to expand cultivation enough that it doesn’t make sense to invert.”

Licensing Gridlock and Market Whiplash

Dispensary operators say New York’s market isn’t just constrained by bureaucracy, it’s tangled in its own rules. Jon Paul Pezzo, owner of NYC Bud dispensary, believes the state’s proximity restrictions have unintentionally frozen the licensing process. “You have a lot of people that are holding proximities because they’re in the December queue or they just have a proximity,” he explained. “Some may have abandoned their license or run out of money, but those spots are still locked up. That means someone with an actual license can’t move forward.” Pezzo said that while rolling out the market slowly may have helped at first, the process has caused problems on all sides.

Now that the agency is considering waiving its 1,000-foot proximity rule to allow more dispensaries to open, Pezzo worries it’s too soon for such sweeping changes. “The industry isn’t even five years old,” he said. “Let it play out before you start rewriting the rules. If we had known these laws would change this quickly, maybe we would have invested differently.”

He added that while OCM claims to solicit feedback from operators, the process feels one-sided. “I’ve been to many OCM meetings where everyone’s frustrated, and the regulators just sit there getting yelled at,” he said. “At some point, they just shut down. I don’t think they’re really listening to logic.”

The Data Gap: METRC, Testing, and a Lack of Standards

Ambrosino believes New York’s lack of standardized testing and tracking has left the industry vulnerable to chaos. “If you want a juicy nugget, I’ll tell you where to look,” he said. “It’s in the testing, and it’s in the labs. If you dig deep enough, you’ll find that all of our labs are invalid because they were supposed to be updated by Wadsworth Labs, the state police lab that never got the equipment. Because of that, every lab is operating under its own standard. There’s no standardization between labs, and nobody knows.”

That lack of consistency, he warns, could have far-reaching financial consequences. When potency-based taxes were imposed, each lab’s different results meant the state effectively collected taxes on unverified data. “Don’t be surprised if people start demanding money back for what they overpaid in potency taxes,” Ambrosino said.

A long-promised track-and-trace system could have helped prevent some of this disarray, but the rollout has been repeatedly delayed. After three years, the agency now says METRC will finally be implemented in January.

Jon Paul Pezzo says the delay has left retailers struggling with manual systems that are prone to human error. “In a perfect world, this should work like a supermarket—product comes in, product goes out, and it’s all scanned into one universal system,” he explained. “Instead, we’re manually entering everything, and that leads to mislabeled products and bad data. For something that’s a controlled substance, that’s unacceptable.”

He believes a fully integrated METRC system could finally bring order to the process. “You’d have cultivators logging shipments, dispensaries scanning them in, and all the details automatically syncing,” Pezzo said. “It would make everyone’s life easier and protect the business as a whole. I just don’t understand why it’s taken this long.”

The Hemp Loophole is Undermining New York’s Legal Market

“The entire industry is using the hemp loophole,” Ambrosino said, describing a troubling double standard: OCM forced him to remove hemp-derived products from his website even though the regulations permitted out-of-state sales for products under the .3% threshold, while companies like Sluggers continue to sell high-potency “THCA hemp” products directly to New Yorkers online.

“This stuff they’re calling hemp, it’s not hemp, it’s marijuana,” he said. “We have to be smarter. It’s deceptive, and it’s hurting the legal operators who are trying to play by the rules.”

Ambrosino says that without proper lab oversight and product tracking, hemp-derived cannabinoids like THCA are slipping through regulatory cracks, further undermining the licensed market.

How Cannabis Moves Around the World: Inside the Global Supply Chain

By Pam Chmiel
No Comments

Global cannabis trade is well underway as legalized countries move forward to establish a supply chain infrastructure in a newly formed and rapidly evolving industry. At the forefront of transportation logistics is Cannabilog, an Israeli company led by pharmaceutical industry veteran Yoram Eshel. In an interview, he shared his playbook for building a compliant, efficient, and scalable supply chain for global cannabis import and export trade.

 

The Complex Web of Global Cannabis Trade Regulations

According to Eshel, not surprisingly, the global cannabis trade hinges on regulatory compliance and requires expertise to manage the movement of products across continents. Unlike pharmaceuticals, where harmonized frameworks such as those of the European Union apply across borders, cannabis regulations differ drastically from country to country.

Some nations permit imports, while others ban them entirely. Even within importing countries, the rules vary by product category. “Some will allow flower, others only oil or genetics,” Eshel explains. “It’s never a simple straight line.”

Every aspect of the supply chain requires specific licensing under narcotics laws, from cultivation and storage to import and export. Adding to the challenge is the constant evolution of these laws. For example, Thailand initially embraced its booming local market and export-friendly policies, but the new government abruptly switched course and limited cannabis use to medical purposes only. In addition, Thai producers seeking to export face roadblocks because European authorities do not recognize their local GACP certifications, which are based on “Good Cultivation and Harvesting Practices for Medicinal Plants.”

Eshel emphasizes that failing to keep pace with changing laws can be costly.

 

“If you export cannabis products to another country and they can’t clear customs, the shipment is destroyed. There’s no way back.”

 

Medical Cannabis Must Meet Pharmaceutical Standards

The second major pillar of the international cannabis trade is adherence to pharmaceutical-grade standards. “Governments treat medical cannabis as a medicine,” says Eshel. “It’s exactly like Tylenol or any other drug.”

Even though cannabis has not gone through the traditional drug registration process, regulators treat it as a pharmaceutical product, which means it must comply with strict Good Distribution Practice (GDP) requirements. That includes temperature control, data logging, and rigorous quality management throughout the supply chain. Every shipment is audited and must be approved by a Qualified Person (QP) on the receiving end before entering the market. If any quality parameters are unmet, the product is rejected.

Logistics providers like Cannabilog must operate under EU GDP certification and maintain pharmaceutical-grade systems and documentation. “We are audited constantly,” Eshel says.

The difference between the medical and recreational markets often catches producers off guard, especially those in countries like Canada, which has a more recreational mindset, similar to that of the US. “When you move into the medical space,” Eshel notes, “you suddenly need temperature-controlled vehicles, validated packaging, and specialized labeling. It requires training and experience.”

Globally, countries such as Germany, Australia, and Israel classify cannabis exclusively as a medical product. “It’s not even close to recreational,” Eshel stresses. “And in most countries, recreational use is still illegal and requires special licensing.”

 

Managing Cold Chain Logistics

After navigating complex regulations and meeting pharmaceutical-grade standards, the final piece of the international cannabis trade puzzle, says Eshel, is execution.

 

“You can have your licenses, your permits, your quality system, but if you don’t execute correctly, everything can fail.”

 

Execution means maintaining control over every step, including packaging, labeling, documentation, temperature regulation, and secure transportation. Shipments must move through carefully selected routes using temperature-controlled vehicles, warehouses, and flights, with continuous monitoring to ensure product integrity is preserved. In some countries, even armed escorts are required for security.

Eshel explains that cannabis logistics is not one-size-fits-all. Each product type, including genetics, flower, and concentrates, has unique handling and storage protocols. For instance, cannabis clones present one of the most challenging forms of transport. “Most clones are unrooted,” he says. “From the moment you cut them from the mother plant, you have three to four days to keep them alive. That requires special packaging, rapid shipping, and customs clearance to get them back into water in time.”

Temperature management is another major operational challenge. Most global regulators require cannabis products to be stored and transported between 59 °F and 77 °F, known in the pharmaceutical world as Controlled Room Temperature (CRT). In the United States, many recommend that temperatures should not exceed 70 °F for optimal cannabis preservation. Eshel clarifies that maintaining actual CRT conditions demands active temperature monitoring and specialized packaging, not just insulated boxes.

For every shipment, Cannabilog conducts a route risk assessment to evaluate potential environmental extremes along the supply chain. Eshel cites the example of shipments from Canada to Australia, where opposite seasons create complex thermal risks.

 

“Winter in Canada is summer in Australia, making temperature management a challenge from continent to continent; you have to plan for that,” he says.

 

To minimize exposure, Cannabilog uses pharma-grade airline partners that store and handle products under strict temperature conditions and prioritize loading and unloading to reduce time on the tarmac. Each shipment includes data loggers that record temperature throughout transit.

 

“If there’s an excursion outside the allowed range,” Eshel notes, “the products are rejected.”

 

European regulators, he adds, tend to enforce these standards more rigorously than their U.S. counterparts. While the United States has many GMP-certified cannabis facilities, most are not EU-GMP certified, which limits their ability to export to Europe when the time comes, even though the differences are not that big.

Eshel contrasts this with Canada, where much of the market remains recreational. While medical exporters adhere to strict temperature control and quality management, domestic recreational products are often transported under looser conditions.

 

“You can’t count on the weather,” he says. “Temperature management is part of the medical cannabis infrastructure.”

 

The Last Mile in Cannabis Preservation

Most of Cannabilog’s shipments are from a cultivation or production facility to a licensed wholesaler or distribution center, rather than directly to pharmacies.

 

“We verify that every facility we deliver to is properly licensed and has temperature-controlled storage,” Eshel says.

 

Cannabilog provides insurance coverage for every shipment, including losses related to temperature excursions or other transport issues. However, ultimate product responsibility remains with the manufacturer, much like in the pharmaceutical industry.

 

“If something goes wrong, it’s the manufacturer’s duty to investigate, and if needed, issue a recall,” Eshel explains.

 

Each transfer of custody, whether at the port, airport, or distribution warehouse, marks a shift in responsibility defined by the buyer-seller agreement. Still, Eshel stresses that all parties must adhere to Good Distribution Practices (GDP) and maintain detailed documentation, including lab tests and Certificates of Analysis (COAs), to ensure transparency and traceability.

Without mandatory cold-chain standards, products are often transported in “hot trucks,” leading to product degradation. Eshel agrees: “The last mile is often the weakest link in the supply chain infrastructure as the industry strives to build a cold chain custody from seed to sale.”

Even last-mile deliveries must be temperature-controlled. The difference, Eshel says, comes down to mentality. “In Europe, it’s purely medical. There’s no confusion between recreational and medical use, so cannabis is treated just like any other medicine.”

 

The United Nations Poised To Recognize Cannabis Culture

No Comments

Beyond its wellness benefits, cannabis carries a rich and diverse cultural legacy that spans the globe. In a  technical paper submitted to Mondiacult 2025, the Cannabis Embassy calls for global recognition of cannabis cultures as an integral part of humanity’s cultural diversity, and as essential to building inclusive, rights-based, and peace-oriented cultural policies in the 21st century.

Mondiacult 2025, UNESCO’s World Conference on Cultural Policies and Sustainable Development, will be held in Barcelona, Spain, from September 29 to October 1, 2025. The gathering brings together ministers, policymakers, cultural professionals, and civil society leaders from all 194 UNESCO Member States to shape the global cultural agenda for the years ahead.

The Roots of Cultural Erasure

The paper begins by tracing how cannabis’s regulation transformed into prohibition. In 1925, the International Opium Convention first put cannabis derivatives under international control. But it was the 1961 Single Convention on Narcotic Drugs that went further, specifically mandating in its Article 49 that traditional or non-medical uses of cannabis should be “abolished” as soon as possible.

This legal architecture effectively criminalized centuries of cultural practices almost overnight, without regard for the histories, traditions, or worldviews of communities that had used cannabis as part of their heritage.

The authors highlight a stark paradox: although Article 49 attempts to eradicate non-medical uses, cannabis use and culture never disappeared. Instead, they persisted and adapted underground, often at great social and legal risk to the people involved.

Culture of Resilience

Criminalization has driven cannabis traditions underground, disrupting the transfer of knowledge across generations and forcing communities to safeguard their heritage in secrecy. The war on drugs has made it risky to openly celebrate or develop cultural practices tied to the plant.

Yet despite decades of stigma and repression, cannabis cultures have shown remarkable resilience. Communities have preserved knowledge orally, sustained clandestine cultivation networks, and reinvented social practices to keep traditions alive.

Still, criminalization has silenced open expression, marginalized traditional growers and knowledge holders, and left indigenous and legacy communities sidelined in legalization efforts that rarely create fair or inclusive opportunities.

Human Rights, Cultural Rights & the Need for Reconciliation

The technical paper frames this struggle in the language of cultural and human rights. International human rights instruments (e.g., UDHR, ICESCR, ICCPR, and treaties protecting indigenous and minority cultures) affirm that all peoples have the right to participate in cultural life, to transmit traditions, and to enjoy “the moral and material interests” tied to their cultural expressions.

Yet, the authors argue, cannabis communities have been systematically denied these rights through prohibition, stigma, and exclusion. Tools of cultural safeguarding (such as UNESCO’s 2003 Convention on the Safeguarding of Intangible Cultural Heritage) have rarely been applied to cannabis-related practices. The paper calls for a recalibration of international norms so that cannabis communities can access recognition, protection, and support.

Policy Recommendations & Pathways Forward

As the world convenes for Mondiacult 2025, this moment presents a window for structural change. The paper sets out key recommendations:

  1. Acknowledge a cultural crisis: explicitly recognize how prohibition has impaired the cultural rights and heritage of cannabis-associated communities.
  2. Reexamine conflicting treaties: address the tensions between Article 49 of the Single Convention and human rights frameworks (UDHR, ICESCR, ICERD).
  3. Support community-led safeguarding efforts by investing in participatory processes to document, revitalize, and protect cannabis-related cultural expressions.
  4. Create enabling environments at national and regional levels, and remove legal and social barriers that prevent communities from freely maintaining or developing their traditions.
  5. Promote equitable benefit–sharing and protections: guard against exploitation or biopiracy of cannabis genetic resources and traditional knowledge.

By recognizing cannabis cultures as part of the global mosaic of cultural expression, and by re-centering rights, dignity, and community control, the authors argue, we can shift from a “war on drugs” mindset toward a culture for peace paradigm.

Read the full report from the Cannabis Embassy here:

From The Lab

An Inside Look at Germany’s Cannabis Supply Chain With The Grünhorn Group

No Comments

On April 1, 2024, Germany launched Pillar 1 of its adult-use legalization framework, building on its established medical cannabis program that has been in place since 2017. Since then, the number of medical patients has surged, as prescriptions remain the only fully legal access point for cannabis aside from home cultivation or membership in non-commercial private clubs, both still limited by incomplete regulations. Unlike the United States, where dispensaries are the backbone of cannabis sales, Germany maintains a more tightly regulated model: patients must secure a doctor’s prescription and fulfill it through a pharmacy.

The next stage, Pillar 2, is expected to introduce licensed retail outlets for adult-use sales, eliminating the requirement for prescriptions. However, with the Christian Democratic Party now in office and maintaining a strong stance against cannabis legalization, these plans face significant uncertainty. While advocates remain hopeful for progress, the CDU’s opposition could delay, restrict, or even reverse parts of the rollout, leaving the future of Germany’s adult-use market in question.

In the meantime, Germany is laying the groundwork for a national infrastructure rooted in its medical system, a stark contrast to the fragmented, state-by-state patchwork in the U.S. This centralized approach not only offers greater oversight and consistency but also positions Germany as a potential model for other European nations exploring reform.

At the center of this rapidly evolving landscape is the Grünhorn Group, one of the country’s most influential players. With an estimated 20 percent market share serving between 5–7 million patients in a nation of 84 million, Grünhorn has established a vertically integrated supply chain that spans importing biomass from global producers, EU-GMP-certified manufacturing, and robust distribution networks. Beyond production, the company operates Germany’s largest online pharmacy platform, giving patients access to products from multiple manufacturers. According to Matthias Fischer, Managing Director of Canymed, Grünhorn’s distribution partner, the group generated €33 million in revenue in 2024, provided medicine to approximately 60,000 patients, and engaged with nearly 6,000 prescribing physicians.

 

Prioritizing Data Collection for Medical Research                                                              For Grünhorn, data is at the core of both its medical mission and its business strategy. The company systematically collects patient feedback on the effects of its products—whether for sleep, anxiety, focus, or other conditions—to inform evidence-based product development. This feedback loop allows Grünhorn to collaborate closely with cultivation partners in designing strains that balance cannabinoids and terpenes to address specific therapeutic needs.

Beyond patient-level insights, Grünhorn is also investing heavily in analytical research. The company operates a gas chromatograph to precisely measure and map the cannabinoid and terpene composition of imported biomass, creating a detailed strain database. To date, Grünhorn has cataloged between 400 and 500 strains of interest, providing one of the most comprehensive genetic and chemical libraries in Germany’s cannabis sector.

“I think the future lies in predicting and knowing which cannabinoids will effectively address specific health indications,” says Fischer, underscoring the company’s long-term vision of turning raw data into targeted, science-driven therapies.

 

Germany is an Import Market

While Germany has licensed domestic cultivation, led by producers such as Tilray, Demecan, and Aurora, the country remains heavily dependent on imports. According to Fischer, the quality of German-grown cannabis has not yet reached the standards set by established cultivation markets in Canada, Portugal, Denmark, and Colombia. To maintain product consistency and meet patient expectations, Grünhorn partners with a Canadian grower, underscoring the ongoing importance of international supply in Germany’s cannabis ecosystem.

Economic factors also weigh heavily on domestic production. High energy costs make large-scale cultivation within Germany particularly challenging, pushing wholesale prices above those of imported flower. As a result, most of the market is supplied by international partners who can cultivate at scale more efficiently and deliver the product at a lower cost.

This reliance on global supply chains is not unique to Grünhorn.

Cantourage, one of Germany’s largest medical cannabis manufacturers, has built its strategy around imports, maintaining partnerships with 40 cultivators across 17 countries. Together, these dynamics reinforce Germany’s role as one of the world’s largest import-driven cannabis markets, even as it develops its own infrastructure.

 

Bottlenecks in the Pharmacy System

Germany’s pharmacy network, spanning both retail and online channels, remains the cornerstone of cannabis dispensing in the country. As patient demand surges, many traditional pharmacies have launched digital platforms to streamline order management. Grünhorn has leaned into this shift, expanding its online pharmacy delivery while forging partnerships with local pharmacists who see cannabis as a valuable revenue driver.

Yet the system is under strain. Because only licensed pharmacists can legally fulfill prescriptions, they often face capacity challenges. Compounding, bottling, labeling, and testing must still be performed manually, creating bottlenecks in day-to-day operations. To keep pace, some pharmacists pre-produce standardized products based on everyday patient needs, despite the model being designed for on-demand compounding. Recognizing these inefficiencies, Grünhorn is investing in custom machinery and software solutions to help pharmacists scale production without compromising compliance, while maintaining oversight of quality and safety.

Another hurdle is product consistency. With prescriptions filled at thousands of independent pharmacies, often by third-party providers, slight variations in formulation are inevitable. “It’s like having 6,000 different factories manufacturing your product,” Fischer explains. To address this, Grünhorn is working on standardized fulfillment models to align independent pharmacies with the quality benchmarks already set by its own online platform.

To further streamline the process, Grünhorn has integrated telemedicine into its supply chain. Patients can now connect directly with physicians, obtain prescriptions, and submit them seamlessly for fulfillment. This innovation helps address a recurring frustration: doctors inadvertently prescribing products that are out of stock, despite having access to inventory databases, ultimately reducing delays and ensuring patients remain on consistent treatment plans.

 

Partnerships and Opportunities                                                                                  Grünhorn’s pharmacy data reveals that 20-30 percent of products generate 80 percent of revenue, indicating a potential for future product consolidation, according to Fischer. For investors, this presents an opportunity to fund medical brands with proven track records that are poised for growth and expansion.

In addition to producing its wholesale product line, Grünhorn is well-positioned and equipped to assist other brands looking to enter the German marketplace and welcomes co-branded product partnerships. They forged a partnership with Somai Pharmaceuticals, based in Portugal, resulting in a two-year, €10 million manufacturing and distribution deal.

Fischer also believes AI will play a significant role in managing the industry in the future, suggesting an opportunity for those looking to enter the German market through technological innovation.

“The biggest challenge we must overcome in the next couple of years is to generate data and medical studies,” Fischer emphasizes. “We have many products with nice ideas, interested patients, and qualifying physicians, but we need more studies and proven evidence to present to new doctors and insurance companies, who are still challenging cannabinoid therapy and requesting data studies.”

For more insights into the German market, listen to an interview with Matthias Fischer on the Innovating Cannabis podcast.

 

Quality From Canada

Inside Red Light Holland’s Plan to Bring Psilocybin Products to the Global Market

By Pam Chmiel
2 Comments

Red Light Holland (CSE: TRIP) has established its foundation in the Netherlands, where psilocybin truffles, the underground sclerotia of psilocybin mushrooms, are legally permitted for cultivation and sale. The above-ground mushroom is prohibited, but the truffle is treated differently under Dutch law, despite delivering the same psychoactive effects.

“It’s really the same thing, with the same effects,” says CEO Todd Shapiro, “but because it forms underground, it can be sold in compliance with Dutch law.”

From its cultivation facility, RLH distributes truffles through a wholesale partnership to over 150 wellness shops under its brands iMicrodose and Maka. “We like to think of them as wellness shops rather than smart shops, like they are referred to in Holland,” Shapiro explains, underscoring the company’s emphasis on education, QR-code-based information, and community engagement. While regulations prevent RLH from turning truffles into edibles such as gummies or chocolates, its vacuum-sealed, raw truffles have become a steady revenue stream. “They’re a bit walnut-y,” Shapiro notes, “but they sell well and people rarely complain.”

 

Canada: Positioning for a Regulated Future                                                           In Canada, RLH is preparing for the potential regulatory shift that could pave the way for the legalization of psilocybin products. The company has already developed psilocybin gummy formulations, but for now, it only sells them as functional mushroom products that don’t contain psilocybin. This approach not only helps build brand recognition, but it also keeps the company R&D-ready, allowing it to move quickly if Health Canada establishes a legal framework for psilocybin.

 

United States: Research Partnerships for Validation                                        South of the border, RLH has partnered with Irvine Labs, a DEA-registered laboratory in California. The lab is testing RLH’s truffles, imported from the Netherlands, to confirm potency, safety, and pharmacological value. The partnership is central to RLH’s long-term vision of formulating psilocybin capsules tailored to various needs, including microdosing, therapeutic use, and wellness.

Shapiro frames the multi-pronged approach as deliberate groundwork for the future. “The Netherlands gives us a legal, revenue-generating business today. Canada positions us for tomorrow. And in the U.S., we’re laying the foundation with science so that when the regulatory environment changes, we’ll be ready.”

 

Research & Consumer Insights                                                                                In addition to building commercial distribution, Red Light Holland is investing in research that could help shape future regulations. Through its iMicrodose app, the company collects voluntary, anonymized data from consumers in the Netherlands on how they are using psilocybin truffles, whether for trauma, pain management, recreation, or general wellness. Shapiro points to a substantial interest in using psilocybin to tame menopause symptoms from their data.

 

“We ask our consumers if they’d like to participate in the app and give us data on how they’re using it,” explains Shapiro.

 

The data was analyzed in collaboration with Drug Science UK under the leadership of renowned neuroscientist Professor David Nutt, one of the most respected voices in psychedelic research and policy. The published study confirmed that RLH’s data provided meaningful evidence of consumer benefit. “A lot of it is anecdotal research, which is key research,” says Shapiro. “It’s almost like its own Phase 1.”

The findings also carried a regulatory impact. RLH presented its consumer data to lawmakers in Oregon as they developed the state’s psilocybin program, contributing to the inclusion of microdosing language in the final bill. “This was a huge win for the company,” Shapiro says. “It adds credibility, validation, and shows how we can responsibly influence policy through science-backed data.”

For RLH, consumer research serves a dual purpose: it provides a self-regulatory framework for the safe distribution of products today, and it informs the company’s plans for future formulations as regulations evolve.

 

Standardization & Medical Pathways                                                                   Red Light Holland is also working behind the scenes to prepare psilocybin for the medical market. The company has partnered with labs in both Canada and the U.S. to analyze and standardize its products, laying the groundwork for future pharmaceutical-style formulations.

In Canada, RLH has collaborated with Seacrest Laboratories in Montreal, securing multiple permits for the import of psilocybin from Health Canada. These projects have produced certificates of analysis (COAs) to understand psilocybin content better and explore standardized dosing formats. “We’re learning about the standardization of our product,” says Shapiro, “whether that eventually becomes ground into powder form or an extract. The end goal is to move toward a consistent, pill-like product for microdosing.”

In the U.S., RLH works with Irvine Labs in California, a rare FDA-approved, DEA-compliant facility, to advance similar objectives. The partnership underscores RLH’s long-term ambition: validating its Dutch truffles as a source for medical-grade psilocybin products that could one day be distributed under compassionate care or special access programs.

“It’s a slow path,” Shapiro admits. “No one would normally start a business that they could only sell in about one percent of the world. But if you want to be an outlier versus an outlaw, you take the careful approach by generating sustainable revenue in Holland while advancing science and regulations in North America.”

 

Slow and Steady                                                                                                    While regulatory doors are starting to crack open in places like Germany, Australia, New Zealand, and the Czech Republic, RLH isn’t rushing in. Shapiro is careful to point out that the company has no interest in repeating the mistakes of many cannabis operators who built massive facilities before the market was ready, only to burn through cash and collapse in oversaturated conditions. Instead, RLH is pacing itself, positioning products, standardizing formulations, and preparing for the moment commercialization becomes viable.

“It’s frustrating for some investors who want instant results,” Shapiro admits, “but the reality is we can only sell in one percent of the world right now. We’d run out of money if we tried to scale too fast. Every move has to be deliberate.”

For RLH, the mission remains steady: take psilocybin from the underground to the mainstream. Until regulations evolve, the company is committed to cautious progress, ensuring it will be ready to deliver once legalization expands.

 

Market Readiness                                                                                                       To help normalize psilocybin, RLH has leveraged functional mushrooms with its Happy Caps grow kits and mushroom gummies to establish brand awareness. Happy Caps started as homegrow kits for lion’s mane, shiitake, and oyster mushrooms, products that ended up on the shelves of Costco and other major Canadian retailers. The idea is simple: just as Canada allowed adults to grow cannabis at home after legalization, psilocybin might one day follow a similar path. If that happens, RLH will already be positioned with both the distribution channels and consumer familiarity to shift from lion’s mane to psilocybin.

More recently, RLH launched mushroom gummies in Canada made with a lion’s mane and shiitake blend. These gummies carry a Health Canada–approved NPN number, which allows the company to make validated health claims, such as immune-boosting and antioxidant properties that most competitors cannot legally advertise. Shapiro says this not only sets RLH apart in the crowded functional mushroom category, but also provides a ready-made blueprint for psilocybin gummies once regulations allow. “It’s a much easier way to consume than chewing on a raw truffle,” he explains. In other words, today’s Happy Caps gummies are tomorrow’s psilocybin edibles.

In parallel, RLH is deepening its scientific foundation through a partnership with Irvine Labs. The company has already imported truffle samples for testing, focusing on potency, shelf-life stability, and consistency—critical steps in moving psilocybin from a naturally variable product to a standardized medicine. “If you’re microdosing for medical reasons, you want to be sure each dose delivers the same effect,” Shapiro explains.

That requires rigorous testing under pharmaceutical standards, much like cannabis research has revealed the complexities of the entourage effect.

Shelf stability has emerged as one of the biggest challenges. Like fresh produce, truffles degrade quickly if not kept under controlled conditions. For RLH, understanding how to preserve potency over time is key to developing future formulations, whether in pill or extraction form. “Consistency is always the goal when it comes to drug discovery,” Shapiro notes.

 

Strategic Growth Through M&A                                                                    Beyond consumer products and R&D, RLH is also exploring mergers and acquisitions as a path to scale. Shapiro says the focus is on acquiring brands with strong recognition and the potential to be cash flow positive, rather than companies burning capital. “A great Instagram account and loyal customers can be half the battle,” he notes. The idea is to consolidate products, share resources, and expand distribution while maintaining financial discipline.

Still, opportunities are scarce. After reviewing more than 40 companies over the past two years, Shapiro says nearly all were losing money. The demands of major retailers compound the challenge—fulfilling large orders requires significant upfront inventory and the ability to survive long payment cycles, which can stretch 90 days or more.

While RLH has heard of pioneering efforts, such as Oregon’s first psilocybin edibles, local ownership laws, and public company reporting requirements make direct entry into that market difficult. For now, the company continues to evaluate partnerships and acquisitions that align with its strategy, while supporting others that advance the industry. As Shapiro puts it, “Rising tides lift all boats.”

 

Looking Ahead                                                                                                        Red Light Holland is narrowing its focus on CPG products, leveraging its experience in the Netherlands while preparing for a global market. While the company continues some cultivation, its strategy centers on creating standardized, science-backed psilocybin products that can reach more people and address the growing mental health crisis. “We’re a psilocybin company at the end of the day,” says Shapiro, “focused on products that can help people, responsibly and sustainably, while navigating complex regulations and building a foundation for future growth.” By combining research, consumer insights, careful regulatory planning, and selective M&A, RLH is positioning itself to take psilocybin from niche wellness shops to mainstream markets worldwide.

From The Lab

MJBowl Comes For New York Brands

By Pam Chmiel
No Comments

MJBizCon, the largest and one of the most influential gatherings in the cannabis industry, is adding a new element to its lineup: a cannabis competition.

This year marks the debut of the MJBowl awards on December 4th in Las Vegas, produced in partnership with Budist, the first-ever review platform to combine consumer feedback with expert ratings from seasoned professionals.

Elevating Cannabis Standards

Often compared to Wine Spectator, the influential magazine known for expert ratings, detailed tasting notes, and industry news, Budist applies a similar model to cannabis.

“Cannabis needed a professional ratings and review platform that elevates a brand’s standards,” said Claudio Miranda, co-founder and COO of Budist. “Just like wine, coffee, or craft beer, cannabis deserves a transparent, unbiased system for measuring quality.”

The inaugural event will feature separate competitions in California and New York, with winners crowned in each state. While future editions may pit markets against one another, for now, the MJBowl is designed as a celebration of excellence rather than a direct state-to-state showdown, since cannabis remains federally illegal and cannot be shipped across state lines.

Driving Premiumization in Cannabis

Beyond ratings and reviews, Budist is also tackling one of the industry’s most persistent challenges: the lack of education around products. Miranda points out that cannabis is often reduced to a race to the bottom, where products are judged primarily on low prices and high THC percentages.

By introducing expert-driven evaluations, Budist aims to help consumers understand why some products command a higher price, just as wine drinkers learn to distinguish between a $10 and a $100 bottle. The platform also shines a spotlight on cultivators and brands that invest in craftsmanship, such as high-quality sun-grown flower, which is often undervalued in today’s market.

“Education is key,” Miranda explained. “Some consumers want value products, and that’s fine. But others are willing to pay more for craftsmanship and quality, and they want to know why that product is worth the premium. That’s where we come in—helping consumers make sense of the differences.”

Budist vs. Ganjier: Complementary Roles

Because Budist is often compared to the Ganjier program, Miranda clarifies the distinction and how they complement one another.

  • Ganjier, founded by renowned cultivator Kevin Jodrey, is the industry’s first sommelier-style certification program. It provides deep product knowledge, professional credentials, and evaluation training similar to earning a degree.
  • Budist is a platform. It gives certified experts, including many Ganjiers, an outlet to apply their skills in the marketplace.

In addition to expert reviews, Budist also includes consumer ratings, creating a dual system modeled after platforms like Rotten Tomatoes, where both critics and everyday users contribute.

 

“Both perspectives are valid,” Miranda said. “Our professionals might include Ganjiers, longtime competition judges, journalists, or educators, but they all share a commitment to standardized, unbiased product evaluation. At the same time, consumer input provides balance and insight into what everyday users value.”

 

Together, programs like Ganjier and platforms like Budist help professionalize cannabis evaluation, giving the industry tools to recognize quality while also educating consumers about the nuances that distinguish one product from another.

California vs. New York: Different Stages, Different Stories

One of the most compelling aspects of the MJBowl will be seeing how winners differ between California and New York.

California has had a legal cannabis framework for over 20 years and is a hub of innovation for brands, product formats, retail experiences, and cultivation and extraction methods. New York’s regulated market, by contrast, is still in its early stages. While its traditional market is longstanding, the legal side has fewer brands and less product diversity, making it more of a developing market than a mature one.

It’s not just about the products. Each MJ Bowl competition reflects the culture of its state. In New York, social equity license holders make up a majority of the market, accounting for approximately 54 percent across cultivation, manufacturing, and retail. Many of these operators come from the legacy market and support one another as they transition into the legal industry. Growers supply brands, brands support retailers, and retailers provide visibility for their community peers. This longstanding network of collaboration is now thriving in the regulated space, giving New York’s cannabis scene a uniquely cooperative spirit.

California, by contrast, brings decades of product innovation and a deep bench of brands, with judges steeped in West Coast cannabis culture. New York’s judging team is being built from within its own community. “This isn’t about California going to New York and telling them what we think of their products,” Miranda said. “It’s about letting each market speak for itself, from producers to consumers and professionals alike.”

How Judges Decide What Wins

According to Miranda, winning products don’t follow a single formula; trends, innovation, and what’s bubbling up in the market all matter. Years ago, hydrocarbon extracts such as shatter and wax dominated competitions, while today’s connoisseurs favor solventless products like rosin. Edibles have evolved from simple brownies to precisely dosed chocolates, beverages, and nanotech-infused products. Judges also reward innovation across hardware and packaging, not just flower or concentrates.

Budist is working to elevate standards by implementing a 100-point evaluation rubric that scores aroma, flavor, appearance, and effect, weighted differently according to category. For example, concentrates are judged heavily on aroma and flavor, while medicinal capsules are judged primarily on whether they deliver the promised effect.

The scoring system also recognizes that consumer expectations vary widely across categories. “You can’t measure rosin against distillate and call one better than the other; they’re different products serving different purposes,” Miranda explained. That’s why products compete within subcategories, ensuring fair comparisons and allowing each style to shine on its own merits.

For the MJBowl, there are five main competition categories:

  • Flower
  • Pre-rolls
  • Vaporizers
  • Concentrates
  • Edibles

Within these, entries are divided into 11 subcategories—such as distillates, live resin, solventless extracts, chocolates, gummies, and beverages to ensure recognition across the full spectrum of cannabis products.

What Winners Receive

In addition to honoring winners on the national stage at MJBizCon, the MJBowl ups the stakes with event tickets, an awards show entry, and a travel voucher to Las Vegas. Winning brands also gain major visibility through post-event press coverage, Budist social promotion, and amplification from MJBiz.

Retail partners in each state, such as The Artist Tree, with 10 California locations, and Gotham, with four dispensaries in New York, have committed to showcasing winners on their shelves.

“This isn’t an award that disappears once the show ends,” Miranda said. “It translates directly into new opportunities for brands. So we hope everybody enters.”

 

Hear Claudio Miranda’s full interview on the Innovating Cannabis Podcast and YouTube.

Arizona Commands the Nation’s Highest Cannabis Business Valuations

By , Gordon K. Sattro
No Comments

Whether it’s a single retail license, a multi-site operation, or a vertically integrated enterprise, deals in Arizona are fetching top-tier premiums – often exceeding price points in larger, more mature markets like California.

So, what’s driving these sky-high valuations? More importantly, how can industry players take advantage? Let’s break it down.

Arizona: Where Cannabis Assets Command a Premium

Over the past 24 months, dozens of transactions have closed in Arizona by way of consolidation, ranging from single dispensary sales to multi-unit portfolio deals. The results have been record-setting: in some cases a standalone retail license has sold for over $10 million, a figure unheard of in many other states. Arizona’s cannabis assets are, in a word, premium and are routinely attracting bids that surpass those in traditionally dominant market.. Clearly, Arizona has become a market where cannabis assets command a serious premium.

Why is this desert market so hot? Below are five key factors fueling Arizona’s elevated valuations.

Five Key Factors Driving Arizona’s Sky-High Cannabis Valuations

  1. Limited License Structure: Arizona’s cannabis market operates under a tightly restrictive license cap, with only 169 dispensary licenses statewide. This built-in scarcity means any available license instantly becomes a coveted asset. With far fewer retail outlets than demand requires, sellers hold the leverage – and can command steep prices as a result.
  2. Dual Licensure (Medical + Recreational): Many Arizona licenses are dual-use, meaning one license allows both medical and adult-use sales. This doubles a dispensary’s potential customer base overnight. Dual licensure translates to higher revenue per store, as each licensed operator can serve all segments of the market. Buyers are willing to pay a premium for this versatility and expanded market share.
  3. Strategic Location and Growing Consumer Base: Arizona boasts one of the fastest-growing populations in the U.S., with major metros like Phoenix and Tucson expanding rapidly. The state also enjoys booming tourist traffic and steady streams of interstate shoppers (especially from nearby prohibition states such as Texas, Utah, and New Mexico). On top of that, Arizona offers a favorable business climate with relatively low taxes and fees, which further boosts profitability for operators. In short, demand is high and operating costs are relatively manageable which all results in a perfect recipe for rich valuations.
  4. Robust Sales and Profitability: Thanks to limited competition and dual-use sales, Arizona dispensaries tend to generate strong revenues and healthy profit margins. Each store services a large customer pool, often resulting in higher sales per dispensary than in states with more saturated markets. Buyers see that Arizona operations can yield a significant return on investment, which justifies paying top dollar for a foothold in the market.
  5. Strong Investor Demand: The buzz around Arizona has drawn in deep-pocketed buyers from across the country. Green Life has witnessed both institutional investors and high-net-worth individuals eagerly bidding for Arizona licenses and companies. This competitive buyer pool pushes valuations even higher – it’s not uncommon to see bidding wars drive a sale price well above the initial asking. When multiple buyers are vying to enter or expand in Arizona, sellers ultimately reap the reward in the form of lofty sale prices.

Navigating the Arizona Market: Buyers and Sellers

Buyers: How to Win in a Hot Market
 For buyers, Arizona’s high valuations mean you must come prepared. To successfully acquire an asset in this competitive market, buyers should:

  • Be ready to move quickly. Attractive opportunities often trigger bidding wars, so speed and decisiveness are essential once a viable deal hits the market.
  • Expect to pay a premium. Understand that Arizona assets are expensive for good reason – low-ball offers won’t win deals here. Savvy buyers budget for top-tier prices and focus on the long-term upside.
  • Leverage local expertise. Partnering with experienced cannabis brokers or advisors (like Green Life Business) who know the Arizona landscape can help you identify opportunities early and navigate the complex regulatory environment with confidence.

Sellers: How to Maximize Your Sale
 For sellers, Arizona’s moment in the spotlight presents a prime opportunity – but preparation is key to capturing maximum value. Green Life Business guides sellers through critical steps to capitalize on the market, including:

  • Packaging the business for maximum value. We help organize financials, compliance records, and growth stories into a compelling presentation that attracts top-tier buyers.
  • Securing pre-qualified buyers. Through an extensive network, we screen and line up buyers who have the interest and the funds, ensuring a smoother sale process.
  • Navigating regulatory hurdles. From state licensing rules to local regulations, our team helps sellers handle all compliance and license transfer requirements without derailment.
  • Closing quickly and transparently. We strive for deals that close on time, with no surprises, giving both parties confidence from offer to final handshake.

By taking these steps, sellers can tap into Arizona’s aggressive pricing environment and drive their deal to the finish line efficiently.

Bottom Line


Arizona isn’t just hot – it’s on fire. In a market where asset values elsewhere are cooling, Arizona continues to deliver record-setting valuations fueled by scarcity, strong demand, and proven profitability.

With experience selling High Times, Statehouse, and securing the largest all-cash cannabis transaction since 2022, Green Life Business has the expertise and track record to position your Arizona business for the strongest possible sale outcome. Whether you’re considering an exit, recapitalization, or expansion, our team brings the market knowledge and deal execution needed to maximize value.

Let’s talk. The next great Arizona transaction could be yours.

Greenlife Business Group Inc.

NECANN Atlantic City: Insights on NJ’s Emerging Market

By Pam Chmiel
No Comments

The excitement and interest around New Jersey are impossible to ignore because of its potential to be one of the most lucrative cannabis markets in the country. Since legalization, operators have been racing to open doors, capture consumers, and keep pace with evolving regulations, as they battle sky-high operating costs, shifting compliance rules, and the uncertainty of how consumer demand will shake out.

At NECANN’s Atlantic City conference, a panel of industry insiders gathered to offer their insights on where the Garden State’s market is heading. Moderated by Jacob Robbins of Longview Strategic, the panel brought together voices from the packaging, brewing, and manufacturing industries to explore the opportunities, roadblocks, and trends reshaping the industry.

“This market is young and growing fast,” Robbins said as he opened the session. “But it’s also unpredictable. Success requires both planning and adaptability.”

Lesson From Other States: Scaling Smart                                                                                    Jason Marshall of AE Global, a company specializing in packaging and supply chain solutions, began by pointing to lessons from more mature cannabis markets. Drawing on his background in consumer packaged goods (CPG) with companies like Pepsi and General Mills, Marshall stressed that packaging in cannabis is far more than just compliance.

“Packaging is the vehicle for trust and brand identity,” he said. “In a crowded dispensary, that’s how you stand out.”

The data shows just how crowded New Jersey has become. In 2023, the state tracked 2,100 SKUs; this year, that number more than doubled to 4,800. For consumers, that means unprecedented choice. For businesses, it means competing for shelf space and consumer attention in ways that look increasingly like mainstream retail.

Marshall’s advice was clear: treat cannabis like any other consumer market. Strategic planning is essential, but rigid strategies rarely succeed. Operators must be nimble and prepared to adjust pricing, packaging, and distribution to reflect changing consumer behavior and evolving regulatory requirements. “The playbook is always shifting,” Marshall said. “The winners are the ones who can shift with it.”

Regulations vs. Market Reality                                                                                                           If packaging is where brands differentiate, regulation is where they stumble. Chuck Garrity, founder of Death of the Fox Brewing Co., knows firsthand what happens when rules lag behind business. His experience navigating New Jersey’s craft beer rollout gave him a sobering perspective on what to expect when he entered the cannabis industry with his dispensary, Frosted Nug.

“We saw the same messy process with craft beer,” Garrity said. “Government always lags behind business. Cannabis is no different.”

According to Garrity, the problem isn’t just bureaucracy; it’s who writes the rules. Lobbyists, he argued, play an outsized role in shaping legislation. Unless operators engage lawmakers directly, they risk being boxed out of decisions that will shape their businesses for decades.

“Operators need relationships with mayors, senators, and regulators. If you’re not at the table, you’re on the menu,” he warned.

The threat of overregulation is real. Rules that are too restrictive, he said, could choke off innovation and slow down the momentum New Jersey needs to stay competitive with neighboring states. For Garrity, political advocacy is not optional; it’s survival.

Manufacturing, Innovation, and White Labeling                                                      Where Garrity sees a risk in policy, Hursh Patel sees opportunity in production. Patel, founder of Red Oak Cannabis, detailed his company’s investment in a CGMP-certified manufacturing facility powered by AI-driven automation to raise the bar on quality, consistency, and efficiency.

“Automation and quality control are everything in cannabis manufacturing,” Patel said. Consumers expect consistency. Retailers demand it. AI helps us deliver it at scale.”

But Patel’s bigger play is in white-labeling. In a landscape where every dispensary is trying to carve out its identity, exclusive brands offer a way to build loyalty and improve margins.

“White label gives retailers the chance to control more of the value chain,” Patel explained. “It’s a high-margin growth path, but it only works with the right partners and strict quality standards.”

The strategy has been successful in other states, where dispensaries have developed in-house brands that compete directly with national players. In a crowded New Jersey market, Patel argued, it could mean the difference between profitability and mediocrity.

Beverages: The Next Super-Category                                                          One trend drew universal attention: beverages. While still a small slice of the market, cannabis drinks are gaining momentum across the U.S., and panelists believe New Jersey won’t be far behind.

Marshall pointed to the West Coast, where dispensaries in California and Oregon are increasingly “fridge-heavy,” dedicating prime space to cannabis beverages. Branding is more experiential, with products designed to appeal to wellness-minded and socially conscious consumers who might never consider smoking a joint.

“Beverages are shaping up to be a super-category,” Marshall said. “In three to five years, they could be the preferred consumption method.”

National brands like Cycling Frog are already building mainstream awareness, helping normalize the idea of drinking cannabis instead of alcohol. For New Jersey operators, beverages represent both an opportunity and a challenge: they require cold storage, different packaging standards, and consumer education. But if the predictions hold true, they could also be the next major driver of growth for dispensaries.

Roadblocks On The Horizon                                                                         Despite the optimism, delivery remains an obstacle, being both costly and underdeveloped. Insurance premiums are steep, and regulations create more friction than efficiency. Without reform, consumers may continue to rely on traditional purchasing channels.

Interstate commerce also looms large. While federal legalization remains stalled, most agree that it’s a matter of when, not if. For New Jersey, with its high operating costs, the threat is real. Once interstate trade opens, local producers may struggle to compete with lower-cost operators on the West Coast.

Then there’s politics. New Jersey’s upcoming gubernatorial election could have a major impact on the regulatory climate. A shift in leadership could accelerate reform or stall it indefinitely.

Key Takeaways for New Jersey Operators                                                  By the end of the session, a handful of themes emerged as survival strategies for cannabis businesses in the Garden State:

  1. Build flexibility into strategy. The rules and market conditions will change—your business model must be ready to adapt.
  2. Study other state markets. Learn from the missteps and successes of other states.
  3. Cultivate political relationships. Lobbying power isn’t optional; it’s how laws get written.
  4. Explore white-label opportunities. House brands can expand margins and consumer loyalty.
  5. Prepare for beverages. There seems to be a big white space for beverages. Whether it’s in two years or five, drinks are poised to lead consumer adoption.

A Market Still Taking Shape                                                                         The challenges are significant, and the future is uncertain, just like any other maturing cannabis market. But for operators willing to stay lean, resourceful, invest in relationships, and think creatively about products, the opportunity remains immense.

“This is still the early innings,” Robbins said in closing. “The operators who thrive will be the ones who treat this like the serious, dynamic consumer market it is, while never forgetting that in cannabis, everything can change overnight.”

 

What you will learn:

  • What makes New Jersey one of the most promising cannabis markets in the U.S.?

  • How are operators adapting to high operating costs and changing regulations?

  • What lessons can New Jersey learn from more mature cannabis markets?

  • Why is packaging important for brand identity and consumer trust in cannabis?

  • How can white-label products help dispensaries improve margins and loyalty?

  • Why are cannabis beverages considered a potential “super-category” for growth?

  • What regulatory and political challenges could impact New Jersey operators?

  • How can operators stay flexible and thrive in a rapidly evolving cannabis market?

Making the Cannabis Industry SAFER for America

By Melissa Kuipers Blake, Osiris Morel
No Comments

After nearly a decade of conversation and education on the Hill, the Senate Banking, Housing and Urban Affairs Committee finally held a markup on the Secure and Fair Regulation (SAFER) Banking Act. Previously known as the SAFE Banking Act, the “R” was included to account for Sen. Jack Reed’s (D-RI) concerns with Section 10. The senator shared his concerns publicly on May 11 during the “Examining Cannabis Banking Challenges of Small Businesses and Workers” hearing. Sen. Reed said that Section 10’s language “would make it more difficult for federal regulators to raise the alarm about relationships with any customer that presents significant risks to the bank” and shared that such a provision is “not limited to the marijuana industry or the cannabis industry,” but that it “could allow pyramid schemes or all sorts of other interesting activity to go on without an effective response by the regulator.” Since then, he and a group of bipartisan members, including Majority Leader Chuck Schumer (D-NY), Senate Banking Committee Chair Sherrod Brown (D-OH), and Sens. Steve Daines (R-MT), Cynthia Lummis (R-WY), Kevin Cramer (R-ND) and Kyrsten Sinema (I-AZ), have worked endlessly to develop language to resolve such concerns while maintaining GOP support, leading to the SAFER Banking Act.

Number of Depository Institutions Actively Banking
Cannabis-Related Businesses in the United States
(Reported in SARS)

The difference between the SAFE Banking Act and the SAFER Banking Act can mainly be found in Section 10. Changes focus on and determines:

  • How regulators terminate bank accounts;
  • How the Federal Deposit Insurance Corporation (FDIC) develops guidance for financial institutions serving state-licensed cannabis businesses;
  • How income derived from state-legal cannabis business activity is managed;
  • That personal and political beliefs cannot impact a financial regulator’s decision making;
  • That federal banking regulators and state banking supervisors and their secretaries of Commerce and Treasury would create rules to increase access to deposit accounts and how such individuals would enhance customer relationships with rural, low- and moderate-income, unbanked and tribal communities; and
  • How the FDIC would conduct a biennial survey and report on barriers for small- and medium-sized businesses.

During the markup on Wednesday, members introduced and discussed a range of amendments related to criminal justice reform, the racial wealth gap, federal regulators and their processes, rescheduling and the opioid epidemic. In total, there were six amendments, one by Chairman Brown, as well as Sens. Mike Crapo (R-ID), Bill Hagerty (R-TN), Mike Rounds (R-SD) and two by Sen. Raphael Warnock (D-GA). Sen. Brown’s amendment, which would make technical changes to the bill, was the only amendment to prevail on a 17-6 vote.

Senate Majority Leader Chuck Schumer (center), Senate Finance Committee Chair Ron Wyden (right) and Senator Cory Booker (left)

To begin the markup, Chair Brown said that propelling this legislation is a critical step in reversing the damage done by the war on drugs and clarified that the SAFER Banking Act would create a better financial system for small and medium-sized cannabis businesses that lack access to such traditional banking services. Sen. Daines, who served as the committee ranking member in place of Sen. Tim Scott (R-SC), who was in California preparing for the Republican presidential debate, shared that although he opposes legalization or decriminalization, he agreed to sponsor and support the SAFER Banking Act because it would fix the current banking system for cannabis businesses nationwide. After hearing remarks from Sens. Lummis, Catherine Cortez Masto (D-NV) and Sinema, the committee voted on the bill, and approved its passage to the Senate floor on a 14-9 vote. Senators voting in favor of the bill were Brown, Tester, Warren, Reed, Menendez (by proxy), Smith (by proxy), Warner, Fetterman, Cortez-Masto, Sinema, Van Hollen, Lummis, Cramer and Daines, and voting against the measure were Sens. Warnock, Scott (by proxy), Crapo, Tillis, Kennedy, Haggerty, Vance and Britt.

After the vote, Sen. Jeff Merkley (D-OR) thanked Sen. Rand Paul (R-KY) and former Republican Sen. Cory Gardner (CO) for their early efforts and for bringing the legislation and issue to the chamber’s attention and concluded that he hopes to have a robust discussion with the full Senate chamber.

With the bill out of committee, it heads to the Senate floor for additional input, discussion and potentially a vote. Majority Leader Schumer has said he intends to bring the SAFER Banking Act to the floor “with all due speed” and noted that he is committed to attaching Rep. Dave Joyce’s (R-OH) Harnessing Opportunities by Pursuing Expungement (HOPE) Act and Rep. Brian Mast’s (R-FL) Gun Rights and Marijuana (GRAM) Act to the final legislation. Sen. Schumer also shared that such provisions would address the war on drugs, bolster social equity and criminal justice reform and protect Second Amendment rights for medical cannabis patients.

When the SAFER Banking Act will receive floor time remains unclear, but Leader Schumer has made numerous representations that he would like to see it done this year.